Mergers & Acquisitions ·
Skye Bioscience, Inc. received a notice from Nasdaq on August 18, 2026, indicating non-compliance with Listing Rule…
SKYESkye Bioscience, Inc.
Skye Bioscience, Inc. received a notice from Nasdaq on August 18, 2026, indicating non-compliance with Listing Rule 5550(b)(1) due to negative stockholders' equity of ($497,307) as reported in its June 30, 2021, quarterly filing. The company has until October 2, 2026, to submit a compliance plan and may receive an extension until February 14, 2027. Skye is currently evaluating alternatives to regain the required $2,500,000 minimum equity standard. Concurrently, the filing serves as soliciting material for a proposed acquisition of Redx Pharma Limited, with a definitive proxy statement expected to be filed for shareholder approval. The company operates in the biotechnology industry, focusing on drug discovery and development.